Objective To explore the effects of silencing Ether-go-go 1（Eag1） potassium channel by short hairpin RNA（shRNA） on the cell proliferation， cell cycle and expression of cyclin D1／E in osteosarcoma cells. Methods The successfully constructed Ad5-Eag1-shRNA vector was transfected into MG-63 cells （inhibition group）. The MG-63 cells transfected with nonsense sequence（Ad5-Control-shRNA vector） were assigned as empty transfection group and cells without any treatment was used as control group. The reverse transcription polymerase chain reaction and Western blotting were used to detect the mRNA and protein levels of Eag1 in MG-63 cells transfected with Ad5-Eag1-shRNA. Cell proliferation of each group was detected by CCK-8 assay and clone formation assay，respectively. Changes of cell cycle and protein levels of cyclin D1／E were detected by flow cytometry and Western blotting，respectively. After the establishment of osteosarcoma xenograft model in nude mice，the changes of tumor volume were measured in each group. Results The protein and mRNA levels of Eag1 were lower in inhibition group rather than empty transfection group and control group with statistically significance difference（P＜0. 05）. Compared with other two groups， there were decreased cell proliferation，colony formation and the proportion of cells in S phase and cell cycle protein levels but increased proportion of cells in G0／G1 phase in inhibition groups（P＜0.05）. The tumor volume of the inhibition group was smaller than those of the empty transfection group and the control group（P＜0.05）. Conclusion Eag1 silencing could suppress osteosarcoma progression and cell cycle through cyclin D1 and E pathway and suggest that Eag1 may be a novel molecular target for osteosarcoma therapy. The inhibition of Eag1 gene expression by shRNA can inhibit the proliferation and induce G0／G1 arrest，which may be related to the regulation of cyclin D1 and E pathway， and is expected to become a new target for treatment and diagnosis of osteosarcoma.

Objective To explore the effects of sorafenib and inhibitors for mammalian target of rapamycine （mTOR） and PI3K on the proliferation and Ghrelin （GHRL） gene expression of hepatobiliary cancer cells.
MethodsThe invitro cultured human hepatocellular carcinoma SMMC7721 cells and bile ductcarcinoma QBC939 cells were treated with different concentrations（0, 50, 100, 200 μmol/L） of sorafenib， LY294002 （PI3K inhibitor） and Rapamycin （mTOR inhibitor） for 48 h. The proliferation rates of SMMC7721 and QBC939 cells were detected by MTS cell activity assay kit. The mRNA levels of GHRL were detected by quantitative realtime PCR （qPCR） in SMMC 7721 and QBC939 cells. Results Compared with the control group，there were decreased proliferative rates of SMMC7721 and QBC939 cells after the treatment with LY294002， sorafenib and Rapamycin in a dose-dependent manner （P＜0.05）. The qPCR results showed that there was no significant difference between the mRNA levels of GHRL in SMMC7721 cells treated with LY294002 and sorafenib in comparison with the control group （P＞0.05）. However， compared with the control group， the mRNA level of GHRL in the experimental group was increased with the elevated concentration of Rapamycin， and the difference was statistically significant（P＜0.05）. The mRNA levels of GHRL in QBC939 cells treated with LY294002，sorafenib and Rapamycin were higher than those in the control group with statistical significance（P＜0.05）. Conclusion Three agents can inhibit the proliferation of hepatobiliary cancer cells and promote the GHRL expression of QBC939 cells， but only Rapamycin can up regulate the expression of GHRL gene in SMMC7721 cells. The expression of GHRL gene is closely related to the occurrence of hepatocellular carcinoma and cholangiocarcinoma.

ObjectiveTo evaluate the effect and safety of decitabine （DAC） combined HIA regimen （homoharringtonine， idarubicin and cytarabine） and FLAG regimen（fludarabine, cytarabine and granulocyte colonystimulating factor） on relapsed or refractory acute myeloid leukemia （AML）. Methods Fifty patients with relapsed or refractory AML who received chemotherapy were retrospectively analyzed， including 17 patients receiving DAC+HIA regimen as observation group and 33 patients receiving FLAG regimen as control group. The complete remission rate， overall response rates （RR）， overall survival （OS）， relapse free survival （RFS） and adverse reactions rate were observed and analyzed. Kaplan-Meier method was used to estimate survival. Results The complete remission rate of observation group was higher than that of control group （64.7％ vs. 33.3％， P＜0.05）. Median OS and median RFS of observation group did not reach，while median OS and median RFS of control group were 654 d and 612 d. The mortality rates of both groups were 35.3％ and 42.4％，and relapse rates were 18.2％ and 45.5％. Infections with different degrees were the main adverse reaction in both groups （70.6％ vs. 87.8％）. Conclusion Decitabine combined HIA regimen is suitable for relapsed or refractory AML patients which is associated with a higher complete remission rate， and it is safe and reliable.